Other Events ·
Completes MDMA production for Phase 3 PTSD trial in Canada and commercial supply in Australia
OPTHOptimi Health Corp.
Optimi Health Corp. completed a batch of MDMA finished drug product at its GMP facility in British Columbia, expected to support three programs: a proposed Phase 3 clinical trial in Canada enrolling up to 100 veterans and frontline workers for PTSD treatment; a clinical trial in Israel partnered with MAPS; and commercial exports to Australia planned before year-end. The Canadian trial aims to evaluate efficacy using the CAPS-5 scale, with initiation expected in 2027. In Australia, MDMA is prescribed under an Authorised Prescriber Scheme with reimbursement from public and private payers. Optimi Health Corp. operates as a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products for mental health therapies.